NDA 022247 · Wyeth Pharms
Duavee
Bazedoxifene Acetate, Estrogens, Conjugated · Oral · Estrogen
NovelLast checked: Nov 20, 2026Latest source record: Mar 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Oct 3, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
45
9 Phase 3, 3 recruiting
FAERS reports
938
207 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. DUAVEE has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.3) ] • Estrogen therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.2 , 5.4) ] • The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of...
What it is approved for
From the label in effect Jul 31, 2026.
DUAVEE is indicated in women with a uterus for: DUAVEE is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus: • Treatment of moderate to severe vasomotor symptoms associated with menopause ( 1.1 ) • Prevention of postmenopausal osteoporosis ( 1.2 ) Limitation of Use : DUAVEE should be used for the shortest duration consistent with treatment goals and risks for the individual woman ( 1.3 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause 1.2 Prevention of Postmenopausal Osteoporosis 1.3 Important Limitations of Use • Use DUAVEE for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. • When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
Mechanism: DUAVEE pairs conjugated estrogens with bazedoxifene. Conjugated estrogens and bazedoxifene function by binding to and activating estrogen receptors (ER) α and β, which vary in proportion from tissue to tissue. Conjugated estrogens are composed of multiple estrogens and are agonists of ER- α and β. Bazedoxifene is an estrogen agonist/antagonist that acts as an agonist in some estrogen-sensitive tissues and an antagonist in others (e.g., uterus). The pairing of conjugated estrogens with bazedoxifene produces a composite effect that is specific to each target tissue. The bazedoxifene component...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 3, 2013 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelReviewLetterLabel
1 products under this application
- DUAVEE · BAZEDOXIFENE ACETATE EQ 20MG BASE; ESTROGENS, CONJUGATED 0.45MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bazedoxifene" as an intervention, any sponsor and status, largest first.
- Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal WomenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00205777 · 7,609 participants · Start Dec 2001 · Primary completion Sep 2010
Drug: Bazedoxifene Acetate · For: Osteoporosis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 375 sites in all
- Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal WomenPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00675688 · 3,544 participants · Start Apr 2002 · Primary completion Jan 2006
Drug: Bazedoxifene/Conjugate Estrogens (CE); Raloxifene and 1 more · For: Endometrial Hyperplasia; Osteoporosis
- Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal OsteoporosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00808132 · 1,886 participants · Start Jan 2009 · Primary completion Feb 2011
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg and 3 more · For: Menopause; Osteoporosis
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 178 sites in all
- Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal WomenPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00481169 · 1,742 participants · Start Jul 2001 · Primary completion Jul 2004
Drug: Bazedoxifene Acetate (TSE-424) · For: Osteoporosis
- Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal WomenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00242710 · 1,083 participants · Start Sep 2005 · Primary completion Sep 2008
Drug: Bazedoxifene/Conjugated Estrogen; Bazedoxifene/Conjugated Estrogen and 1 more · For: Endometrial Hyperplasia; Osteoporosis
Sites: Upland, California; Inverness, Florida; West Palm Beach, Florida · 9 sites in all
- Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With MenopausePivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00238732 · 650 participants · Start Oct 2005
Drug: Bazedoxifene/Conjugated Estrogen · For: Vaginal Atrophy
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 63 sites in all
- Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian WomenPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00384072 · 500 participants (planned) · Start May 2006
Drug: bazedoxifene BZA-20 · For: Postmenopause; Osteoporosis
Sites: Beijing, China; Nanjing, China; Shanghai, China · 20 sites in all
- Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.Pivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00238745 · 375 participants · Start Aug 2003
Drug: Bazedoxifene; Placebo · For: Postmenopausal Osteoporosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective141
- hot flush78
- nausea42
- muscle spasms41
- off label use39
- weight increased35
- feeling abnormal33
- headache33
- dizziness31
- insomnia31
- pain31
- therapeutic response unexpected25
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 117 |
| 2015 | 260 |
| 2016 | 101 |
| 2017 | 72 |
| 2018 | 58 |
| 2019 | 58 |
| 2020 | 159 |
| 2021 | 23 |
| 2022 | 13 |
| 2023 | 20 |
| 2024 | 29 |
| 2025 | 20 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Duavee (Estrogens,Conj/Bazedoxifene)
2024 spending
$948K
Beneficiaries
705
2,844 claims
Per beneficiary
$1,345
$6.37 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,276,061 |
| 2021 | $5,507 |
| 2022 | $2,610 |
| 2023 | $334,061 |
| 2024 | $948,215 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.
Danan ER, Sowerby C, Ullman KE, et al. · Ann Intern Med 2024 · Systematic Review, Research Support, U.S. Gov't, Non-P.H.S.
- Hormone Therapy and Other Treatments for Symptoms of Menopause.
Hill DA, Crider M, Hill SR · Am Fam Physician 2016 · Systematic Review
- Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A, Ajmera M, Gao E, et al. · Menopause 2024 · Systematic Review, Network Meta-Analysis
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR, Nicolopoulos K, Stringer D, et al. · Calcif Tissue Int 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
Genazzani AR, Monteleone P, Giannini A, et al. · Hum Reprod Update 2021 · Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.